Syros Pharmaceuticals Inc (NASDAQ:SYRS) Receives Average Recommendation of “Buy” from Analysts

Shares of Syros Pharmaceuticals Inc (NASDAQ:SYRS) have been assigned a consensus recommendation of “Buy” from the ten ratings firms that are presently covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $18.50.

SYRS has been the topic of a number of recent analyst reports. Roth Capital initiated coverage on Syros Pharmaceuticals in a research note on Friday, July 12th. They issued a “buy” rating and a $17.00 price objective on the stock. BidaskClub lowered Syros Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday. Zacks Investment Research raised Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, September 18th. Finally, ValuEngine raised Syros Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th.

In related news, major shareholder Venture Fund Vii L.P. Arch sold 63,000 shares of the company’s stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $7.77, for a total value of $489,510.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Richard A. Young sold 25,000 shares of the company’s stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $10.00, for a total value of $250,000.00. The disclosure for this sale can be found here. Corporate insiders own 14.80% of the company’s stock.



Several institutional investors have recently made changes to their positions in SYRS. Bank of Montreal Can increased its holdings in shares of Syros Pharmaceuticals by 11,319.2% in the second quarter. Bank of Montreal Can now owns 2,969 shares of the company’s stock worth $27,000 after acquiring an additional 2,943 shares in the last quarter. BNP Paribas Arbitrage SA bought a new stake in shares of Syros Pharmaceuticals in the first quarter worth about $48,000. Bank of America Corp DE increased its holdings in shares of Syros Pharmaceuticals by 205.9% in the fourth quarter. Bank of America Corp DE now owns 17,400 shares of the company’s stock worth $98,000 after acquiring an additional 11,711 shares in the last quarter. A.R.T. Advisors LLC bought a new stake in shares of Syros Pharmaceuticals in the second quarter worth about $119,000. Finally, Susquehanna International Group LLP bought a new stake in shares of Syros Pharmaceuticals in the second quarter worth about $133,000. Institutional investors own 82.08% of the company’s stock.

Syros Pharmaceuticals stock traded up $0.02 on Wednesday, reaching $10.95. The company’s stock had a trading volume of 5,463 shares, compared to its average volume of 142,619. The company has a debt-to-equity ratio of 0.15, a quick ratio of 8.11 and a current ratio of 8.11. The company has a market cap of $475.31 million, a price-to-earnings ratio of -5.73 and a beta of 1.60. The business’s fifty day moving average price is $10.35 and its 200 day moving average price is $8.15. Syros Pharmaceuticals has a twelve month low of $5.17 and a twelve month high of $12.87.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings data on Thursday, August 1st. The company reported ($0.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.06). The business had revenue of $0.46 million during the quarter, compared to analyst estimates of $0.42 million. Syros Pharmaceuticals had a negative return on equity of 79.79% and a negative net margin of 3,137.55%. As a group, equities analysts forecast that Syros Pharmaceuticals will post -1.94 earnings per share for the current year.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients.

Further Reading: Basic Economics creates winners and losers

Analyst Recommendations for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.